NCT04303156View on ClinicalTrials.gov

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

October 19, 2020

Study Completion Date

October 19, 2020

Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
DRUG

Islatravir

Single oral dose of 60 mg Islatravir administered in capsule form

Trial Locations (2)

10117

Charite Research Organisation GmbH ( Site 0003), Berlin

33014

Clinical Pharmacology of Miami ( Site 0001), Miami

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04303156 - Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026) | Biotech Hunter | Biotech Hunter